Nevro Corp (NVRO)

$5.84 0.00 (N/A)
Market Cap 224.09M
Revenue (ttm) 408.52M
Net Income (ttm) -113.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -27.77%
Debt to Equity Ratio 0.98
Volume 753,600
Avg Vol 1,348,482
Day's Range N/A - N/A
Shares Out 38.37M
Stochastic %K 78%
Beta 0.82
Analysts Hold
Price Target $5.44
suntanner20
suntanner20 Jun. 17 at 8:03 PM
$MLSS all about the contacts. the best in biz is based on contacts $NVRO is where new BoD was from
0 · Reply
suntanner20
suntanner20 Jun. 16 at 3:09 PM
$MLSS someone took size .8950-.91 we MUST be close $NVRO executives ?
0 · Reply
suntanner20
suntanner20 Jun. 13 at 1:17 PM
$MLSS Table Is Set: Everyone needs to eat. In fact, everyone loves to eat a great big home cooked meal, but not everyone loves to do what it takes to deliver that arduous task. That brings us to what potentially could be one of the most savoring investments in the micro cap space that just might be all set up for making that brokerage account adequately full when it’s all said and done. The investment is Milestone Scientific (MLSS .90) a medical device company that specializes in a device that delivers a one of a kind, AI pressurized syringe for the epidural market today, but the platform could bolster many new applications in the not too distant future. The reality is the company has done a lot of the heavy lifting to get themselves to invite as many new shareholders to the table that we believe is set to eat. Shanth Thiyagalingam Brought into MLSS 3 weeks ago COULD be the Chef needed to find all the ingredients $NVRO $ABT
0 · Reply
suntanner20
suntanner20 Jun. 11 at 5:04 PM
$MLSS someone collecting blocks of stock CANNOT BE LONG!!!!! $NVRO
1 · Reply
suntanner20
suntanner20 Jun. 11 at 1:44 PM
$MLSS This is NOT 1.00 stock much longer. I noticed new BoD was at $NVRO 3-50 then 130 cmon 5.00
0 · Reply
BioTechHealthX
BioTechHealthX Jun. 8 at 6:31 PM
$NVRO With groundbreaking tech, strong IP, & rising international demand, Nevro might be undervalued even with the Globus Medical's acquisition. https://biotechhealthx.com/biotech-news/nevro-nvro-could-surge-beyond-its-buyout-offer-in-2025/
0 · Reply
Love_To_Learn
Love_To_Learn Apr. 3 at 1:13 PM
$NVRO coding the halt now
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 21 at 9:46 AM
$NVRO Digging Nevro's AI-powered pain management tech. HFX AdaptivAI looks promising. Might initiate a small position to play the chronic pain innovation angle. Watching closely for clinical expansion potential. noteworthy article: https://beyondspx.com/article/nevro-corp-nvro-delivering-innovative-solutions-for-chronic-pain-management
1 · Reply
Estimize
Estimize Mar. 5 at 11:00 AM
$NVRO reported -1.41 EPS and 105.55 revenue for Q4. http://www.estimize.com/intro/nvro?chart=historical&metric_name=eps&utm_content=NVRO&ut
0 · Reply
Estimize
Estimize Mar. 4 at 4:00 PM
$NVRO reports after the close, Estimize Consensus +0.06 EPS and +1.79M Revs compared to WS http://www.estimize.com/nvro/fq4-2024?utm_conten
0 · Reply
Latest News on NVRO
Nevro Corp. Investigated by Federman & Sherwood for Data Breach

Apr 3, 2025, 4:24 PM EDT - 3 months ago

Nevro Corp. Investigated by Federman & Sherwood for Data Breach

NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp. - NVRO

Mar 21, 2025, 11:30 AM EDT - 3 months ago

NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp. - NVRO

GMED

Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results

Mar 4, 2025, 4:15 PM EST - 4 months ago

Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results

GMED

Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08

Jan 21, 2025, 4:30 PM EST - 5 months ago

Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08

Nevro Announces Preliminary Fourth-Quarter and Full-Year 2024 Revenue Results

Jan 13, 2025, 8:30 AM EST - 5 months ago

Nevro Announces Preliminary Fourth-Quarter and Full-Year 2024 Revenue Results

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

Dec 2, 2024, 2:29 PM EST - 7 months ago

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

GKOS ISRG SYK

New Study Demonstrates Multiple Advantages of Nevro1™, the Novel SI Joint Fusion System by Nevro, in Comparison to Posterolateral and Lateral Approaches

Nov 18, 2024, 8:30 AM EST - 7 months ago

New Study Demonstrates Multiple Advantages of Nevro1™, the Novel SI Joint Fusion System by Nevro, in Comparison to Posterolateral and Lateral Approaches

Nevro's HFX iQ™ Spinal Cord Stimulation with AI Technology Receives CE Mark Certification in Europe, Increasing Product Expansion Globally

Nov 12, 2024, 7:00 AM EST - 8 months ago

Nevro's HFX iQ™ Spinal Cord Stimulation with AI Technology Receives CE Mark Certification in Europe, Increasing Product Expansion Globally

Nevro Corp. (NVRO) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 9:11 PM EST - 8 months ago

Nevro Corp. (NVRO) Q3 2024 Earnings Call Transcript

Nevro Reports Third-Quarter 2024 Financial Results

Nov 11, 2024, 4:05 PM EST - 8 months ago

Nevro Reports Third-Quarter 2024 Financial Results

New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation Therapy

Oct 29, 2024, 4:30 PM EDT - 8 months ago

New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation Therapy

Nevro to Report Third-Quarter 2024 Financial Results and Host Earnings Conference Call on November 11, 2024

Oct 10, 2024, 4:45 PM EDT - 9 months ago

Nevro to Report Third-Quarter 2024 Financial Results and Host Earnings Conference Call on November 11, 2024

Nevro Announces the Launch of HFX AdaptivAI™, the Only AI-Driven Technology in Spinal Cord Stimulation

Sep 24, 2024, 8:00 AM EDT - 9 months ago

Nevro Announces the Launch of HFX AdaptivAI™, the Only AI-Driven Technology in Spinal Cord Stimulation

Nevro to Present at Wells Fargo 2024 Healthcare Conference

Aug 28, 2024, 4:15 PM EDT - 10 months ago

Nevro to Present at Wells Fargo 2024 Healthcare Conference

Nevro: Not Having My Back

Aug 9, 2024, 3:47 PM EDT - 11 months ago

Nevro: Not Having My Back

Nevro Corp. (NVRO) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 5:54 AM EDT - 11 months ago

Nevro Corp. (NVRO) Q2 2024 Earnings Call Transcript

Nevro Reports Second-Quarter 2024 Financial Results

Aug 6, 2024, 4:05 PM EDT - 11 months ago

Nevro Reports Second-Quarter 2024 Financial Results

Nevro to Report Second-Quarter 2024 Financial Results and Host Earnings Conference Call on August 6, 2024

Jul 9, 2024, 4:15 PM EDT - 1 year ago

Nevro to Report Second-Quarter 2024 Financial Results and Host Earnings Conference Call on August 6, 2024

Nevro to Present at Truist Securities MedTech Conference

Jun 11, 2024, 4:15 PM EDT - 1 year ago

Nevro to Present at Truist Securities MedTech Conference

Nevro to Present at BofA Securities 2024 Healthcare Conference

May 9, 2024, 4:05 PM EDT - 1 year ago

Nevro to Present at BofA Securities 2024 Healthcare Conference

Nevro Corp. (NVRO) Q1 2024 Earnings Call Transcript

May 8, 2024, 2:01 AM EDT - 1 year ago

Nevro Corp. (NVRO) Q1 2024 Earnings Call Transcript

Nevro Reports First-Quarter 2024 Financial Results

May 7, 2024, 4:05 PM EDT - 1 year ago

Nevro Reports First-Quarter 2024 Financial Results

Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024

Apr 17, 2024, 8:30 AM EDT - 1 year ago

Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024

Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw

Feb 28, 2024, 4:10 PM EST - 1 year ago

Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw

Nevro Corp. (NVRO) Q4 2023 Earnings Call Transcript

Feb 21, 2024, 11:02 PM EST - 1 year ago

Nevro Corp. (NVRO) Q4 2023 Earnings Call Transcript

Nevro Enters Into Cooperation Agreement With Engaged Capital

Feb 21, 2024, 4:06 PM EST - 1 year ago

Nevro Enters Into Cooperation Agreement With Engaged Capital

Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results

Feb 21, 2024, 4:05 PM EST - 1 year ago

Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results

Nevro Announces Consensus Statement Supporting High-Frequency (10 kHz) Spinal Cord Stimulation Therapy for Refractory Painful Diabetic Neuropathy

Feb 1, 2024, 4:30 PM EST - 1 year ago

Nevro Announces Consensus Statement Supporting High-Frequency (10 kHz) Spinal Cord Stimulation Therapy for Refractory Painful Diabetic Neuropathy

Nevro to Report Fourth-Quarter and Full-Year 2023 Financial Results and Host Conference Call on February 21, 2024

Jan 29, 2024, 4:30 PM EST - 1 year ago

Nevro to Report Fourth-Quarter and Full-Year 2023 Financial Results and Host Conference Call on February 21, 2024

Nevro Announces Positive Coverage Update from Carelon Healthcare for the Treatment of Painful Diabetic Neuropathy

Jan 18, 2024, 4:15 PM EST - 1 year ago

Nevro Announces Positive Coverage Update from Carelon Healthcare for the Treatment of Painful Diabetic Neuropathy

Nevro to Highlight 25 Scientific Abstracts at 2024 North American Neuromodulation Society (NANS) Annual Meeting

Jan 17, 2024, 4:15 PM EST - 1 year ago

Nevro to Highlight 25 Scientific Abstracts at 2024 North American Neuromodulation Society (NANS) Annual Meeting

Nevro laying off 63 employees; revenue to beat analyst estimates

Jan 9, 2024, 8:50 AM EST - 1 year ago

Nevro laying off 63 employees; revenue to beat analyst estimates

Nevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue Results

Jan 9, 2024, 8:30 AM EST - 1 year ago

Nevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue Results

Nevro to Present at 42nd Annual J.P. Morgan Healthcare Conference

Jan 4, 2024, 4:15 PM EST - 1 year ago

Nevro to Present at 42nd Annual J.P. Morgan Healthcare Conference

Nevro Announces Acquisition of Vyrsa™ Technologies

Nov 30, 2023, 5:19 PM EST - 1 year ago

Nevro Announces Acquisition of Vyrsa™ Technologies

Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain

Nov 20, 2023, 7:00 AM EST - 1 year ago

Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain

Nevro Reports Third Quarter 2023 Financial Results, Provides Fourth Quarter Guidance and Updates Full-Year 2023 Guidance

Nov 1, 2023, 4:01 PM EDT - 1 year ago

Nevro Reports Third Quarter 2023 Financial Results, Provides Fourth Quarter Guidance and Updates Full-Year 2023 Guidance

Nevro to Report Third Quarter 2023 Financial Results

Oct 4, 2023, 7:00 AM EDT - 1 year ago

Nevro to Report Third Quarter 2023 Financial Results

New Data Demonstrate the Health Economic Benefits of Nevro's High-Frequency Spinal Cord Stimulation Therapy

Sep 18, 2023, 7:00 AM EDT - 1 year ago

New Data Demonstrate the Health Economic Benefits of Nevro's High-Frequency Spinal Cord Stimulation Therapy

Nevro: Economic Realities Too Deep To Ignore, Downgrade To Hold

Sep 1, 2023, 3:54 PM EDT - 1 year ago

Nevro: Economic Realities Too Deep To Ignore, Downgrade To Hold

Nevro Announces Participation in Upcoming Investor Conferences

Aug 23, 2023, 7:00 AM EDT - 2 years ago

Nevro Announces Participation in Upcoming Investor Conferences

suntanner20
suntanner20 Jun. 17 at 8:03 PM
$MLSS all about the contacts. the best in biz is based on contacts $NVRO is where new BoD was from
0 · Reply
suntanner20
suntanner20 Jun. 16 at 3:09 PM
$MLSS someone took size .8950-.91 we MUST be close $NVRO executives ?
0 · Reply
suntanner20
suntanner20 Jun. 13 at 1:17 PM
$MLSS Table Is Set: Everyone needs to eat. In fact, everyone loves to eat a great big home cooked meal, but not everyone loves to do what it takes to deliver that arduous task. That brings us to what potentially could be one of the most savoring investments in the micro cap space that just might be all set up for making that brokerage account adequately full when it’s all said and done. The investment is Milestone Scientific (MLSS .90) a medical device company that specializes in a device that delivers a one of a kind, AI pressurized syringe for the epidural market today, but the platform could bolster many new applications in the not too distant future. The reality is the company has done a lot of the heavy lifting to get themselves to invite as many new shareholders to the table that we believe is set to eat. Shanth Thiyagalingam Brought into MLSS 3 weeks ago COULD be the Chef needed to find all the ingredients $NVRO $ABT
0 · Reply
suntanner20
suntanner20 Jun. 11 at 5:04 PM
$MLSS someone collecting blocks of stock CANNOT BE LONG!!!!! $NVRO
1 · Reply
suntanner20
suntanner20 Jun. 11 at 1:44 PM
$MLSS This is NOT 1.00 stock much longer. I noticed new BoD was at $NVRO 3-50 then 130 cmon 5.00
0 · Reply
BioTechHealthX
BioTechHealthX Jun. 8 at 6:31 PM
$NVRO With groundbreaking tech, strong IP, & rising international demand, Nevro might be undervalued even with the Globus Medical's acquisition. https://biotechhealthx.com/biotech-news/nevro-nvro-could-surge-beyond-its-buyout-offer-in-2025/
0 · Reply
Love_To_Learn
Love_To_Learn Apr. 3 at 1:13 PM
$NVRO coding the halt now
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 21 at 9:46 AM
$NVRO Digging Nevro's AI-powered pain management tech. HFX AdaptivAI looks promising. Might initiate a small position to play the chronic pain innovation angle. Watching closely for clinical expansion potential. noteworthy article: https://beyondspx.com/article/nevro-corp-nvro-delivering-innovative-solutions-for-chronic-pain-management
1 · Reply
Estimize
Estimize Mar. 5 at 11:00 AM
$NVRO reported -1.41 EPS and 105.55 revenue for Q4. http://www.estimize.com/intro/nvro?chart=historical&metric_name=eps&utm_content=NVRO&ut
0 · Reply
Estimize
Estimize Mar. 4 at 4:00 PM
$NVRO reports after the close, Estimize Consensus +0.06 EPS and +1.79M Revs compared to WS http://www.estimize.com/nvro/fq4-2024?utm_conten
0 · Reply
GDog877
GDog877 Feb. 17 at 6:57 PM
$NVRO Reach out to your local congressperson and ask him or her to cosponsor the Capital Loss Inflation Fairness Act that would see the annual Capital Loss limit increase from $3,000 (originally set 47 years ago in 1978) to over $14,000 and adjusting each year for inflation...imagine what $3,000 would be worth 30 years from now if this never changes....HELP SPREAD THE WORD!!! https://norman.house.gov/news/documentsingle.aspx?DocumentID=1611
0 · Reply
DonCorleone77
DonCorleone77 Feb. 8 at 5:34 PM
$NVRO Nevro upgraded to Hold from Underperform at Jefferies Jefferies upgraded Nevro to Hold from Underperform with a price target of $5.85, up from $4.50, after the company entered into a definitive agreement for Globus Medical to acquire all its shares for $5.85 per share.
0 · Reply
ajmrtxl
ajmrtxl Feb. 6 at 6:48 PM
$NVRO real-time squeeze play
1 · Reply
Muddymac
Muddymac Feb. 6 at 3:05 PM
$NVRO https://stocks.apple.com/A1x9npE6ySxONebBwJHq_7Q Sad ending. $250M valuation is embarrassing.
1 · Reply
HaltTradeAlert
HaltTradeAlert Feb. 6 at 2:32 PM
$NVRO Halt Time: 09:30:41 Issue Symbol: NVRO Reason Code: M Last Price: $5.49 Volume: 57.6 K Members get this halt alert with no delay and with more info: shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!
0 · Reply
Muddymac
Muddymac Jan. 31 at 3:55 AM
$NVRO Stryker announced it is selling off its spinal implant business. They would have been the most logical of the big strategic companies that have a spinal business to acquire NVRO. Makes you wonder if the stim market is stagnating or going backwards.
2 · Reply
GDog877
GDog877 Jan. 30 at 1:19 PM
$NVRO tell your local congressperson to cosponsor the Capital Loss Inflation Fairness Act..... https://norman.house.gov/news/documentsingle.aspx?DocumentID=1611
0 · Reply
GDog877
GDog877 Jan. 14 at 1:08 PM
$NVRO Squeaky wheel gets oiled. Give Missouri District 8 Congressman Jason Smith a call. South Carolina Congressman Ralph Norman's proposed Capital Loss Inflation Fairness Act, which would increase the annual capital loss limit from $3,000 to about $14,000 and counting each year for inflation, has been sitting with Jason Smith as the Chairman of the Ways and Means Committee for the past 2 years, and he's thwarted the bill and refused to do anything with it. The buck stops with him in this case. Here's the most direct number to reach him...573-364-2455. And here is all of his contact information. Let's all call him...Since he wants to carelessly ignore an important piece of legislation that would help so many average everyday people, let his phone ring off the hook about it. https://pluralpolicy.com/app/person/7744/bills-sponsored?page=1..
0 · Reply
BPharmCatalyst
BPharmCatalyst Jan. 13 at 9:38 PM
$PHIO shares closed up 291% at $6.6 following results from the second dose cohort of its ongoing Phase 1b trial evaluating intratumoral PH-762 in various skin cancers. See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2025/phio-phio-phase-1b-data-salarius-slrx-decoy-merger $PHIO $SLRX $NAYA $SAGE $ITCI $TRAW $MRNA $NVRO
0 · Reply